Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243 is registered in ClinicalTrials.gov with Kinevant Sciences GmbH as lead sponsor.

NCT NCT04351243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04351243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Lead sponsor
Kinevant Sciences GmbH
Phase
Phase 2
Overall status
Completed
Start date
April 15, 2020
Completion date
April 1, 2021
Enrollment
227 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19